Personalized tumor vaccine shows promise in pilot trial

A new type of cancer vaccine has yielded promising results in an initial clinical trial. The personalized vaccine is made from patients’ own immune cells, which are exposed to the contents of the patients’ tumor cells, and injected into the patients to initiate a wider immune response. The trial, conducted in advanced ovarian cancer patients, showed that about half of the vaccinated patients had signs of anti-tumor T-cell responses.